St Andrews, UK — September 17, 2025 — Leads & Copy — Pneumagen, a clinical-stage biotech company, has launched its NeumoBind™ technology platform, a novel approach to enhance protein delivery to nasal and other mucosal surfaces. The technology addresses the challenge of rapid clearance in mucosal drug delivery by anchoring proteins in place, enabling enhanced residence time, longer-lasting therapeutic activity, and improved efficacy.
With significant intellectual property secured, Pneumagen is investigating the potential of NeumoBind™ to extend residence time on the nasal mucosa when conjugated to therapeutic proteins. Pre-clinical work to investigate nasal residence time of a selected therapeutic protein has already begun, and the Company is also continuing to examine the impact on antibody residence time.
Professor Garry Taylor, Chair of the Scientific Advisory Board of Pneumagen, believes the technology has the potential to open up new opportunities for protein delivery to any mucosal surface, supporting improved efficacy and greater convenience for patients.
Douglas Thomson, Chief Executive Officer at Pneumagen, said NeumoBind™ represents a major step forward in enabling the mucosal delivery of a wide variety of proteins. He added that the company is excited to explore partnerships with companies developing therapeutic proteins and antibodies that could benefit from mucosal delivery.
Pneumagen’s lead candidate, Neumifil, has demonstrated efficacy against multiple respiratory pathogens in pre-clinical models and delivered best-in-class clinical results supporting its potential as a broad-spectrum, intranasal antiviral. Further clinical studies are planned to evaluate Neumifil’s ability to reduce the incidence of viral-induced exacerbations in patients with underlying risk factors.
About Pneumagen: Pneumagen is developing Neumifil, a broad-spectrum antiviral drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs). Neumifil is a novel, engineered, multivalent, Carbohydrate Binding Module (mCBM) that acts by directly binding and preventing the entry into the host of the viral pathogens. Pneumagen was established in 2016 as a spin-out from the University of St Andrews in Scotland.
Contact: Douglas Thomson, CEO, Email: info@pneumagen.com; Sandi Greenwood, Frazer Hall, Email: Pneumagen@medistrava.com
Source: Pneumagen
